Suven Life Sciences Limited

BSE: 530239 NSE: SUVEN
Suven Life Sciences Limited - pharma in Hyderabad, Telangana, India. FY 2026 financials and compliance.
CIN L24110TG1989PLC009713 Incorporated 09 March 1989 ROC Hyderabad HQ Hyderabad, Telangana, India
Active Listed - NSE: SUVEN · BSE: 530239 Public Limited Company pharma
Data last updated
Revenue · FY 2026
₹7.11 Cr
▲ 6.89% YoY
Computed EBITDA · FY 2026
-₹270.57 Cr
▼ 74.7% YoY
Net profit · FY 2026
-₹276.34 Cr
▼ 71.91% YoY
Authorised capital
₹50 Cr
Registered with MCA
Paid-up capital
₹26.4 Cr
Issued & subscribed
Open charges
None
Satisfied ₹239.04 Cr
Company age
37 yrs
Est. 1989
Employees · EPFO
137
Latest available

About Suven Life Sciences Limited

Data last updated: 15 July 2026

Suven Life Sciences Limited is a public limited company based in Hyderabad, Telangana, India, a subsidiary of Jasti Property And Equity Holdings Private Limited. It specialises in pharma contract r and d, a part of the broader pharmaceuticals sector. Incorporated on 09 March 1989, the company has been in operation for over 37 years.

Registered with ROC Hyderabad under CIN L24110TG1989PLC009713. Listed on BSE: 530239 and NSE: SUVEN.

Capital: an authorised share capital of ₹50 Cr and a paid-up capital of ₹26.4 Cr. Formerly known as Suven Synthesis Ltd and Suven Pharmaceuticals Pvt Ltd. It is led by directors including Santanu Mukherjee and Sudharani Jasti.

Last AGM: 22 August 2025. Financial statements filed for year ended 31 March 2025. Office: Door No. 8 – 2 – 334 6Th Floor Sde Serene Chambers Road No. 5 Avenue 7 Banjara Hills, Hyderabad, Telangana, India – 500034.

As per NSE-filed consolidated financials for FY 2026, the company reported a revenue of ₹7.11 Cr, a growth of 6.89% compared to the previous year. The net worth stands at ₹591.4 Cr (up 437.7% YoY). Total assets are valued at ₹624.21 Cr (up 361.75% YoY).

The company has a workforce of approximately 137 employees as per the latest available data. It operates as a subsidiary of Jasti Property And Equity Holdings Private Limited.

The company is associated with 3 brands - Suven Nishtaa, Suven Life Sciences, Suven Pharma. As per MCA filings, the company has satisfied charges of ₹239.04 Cr on record.

The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website suven.com.

Company Details of Suven Life Sciences Limited
CIN L24110TG1989PLC009713
Registration Number 009713
Incorporation Date 09 March 1989
ROC Hyderabad
Listing Status Listed (BSE: 530239, NSE: SUVEN)
Company Status Active
Date of Last AGM 22 August 2025
Date of Balance Sheet 31 March 2025
Parent Company Jasti Property And Equity Holdings Private Limited
Compliance Status Active Compliant
Key People
Venkateswarlu Jasti Managing Director Sudharani Jasti Whole-Time Director Santanu Mukherjee Director
Contact Details
  • Email
    Locked
  • Telephone
    Locked
  • Website
    suven.com
  • Social Media
  • Registered Address
    Door No. 8 – 2 – 334 6Th Floor Sde Serene Chambers Road No. 5 Avenue 7 Banjara Hills, Hyderabad, Telangana, India – 500034
  • Industry
    Pharma, Pharma Contract R&D
Company report
Suven Life Sciences Limited - full intelligence report
  • Historical Financials and ratios
  • Shareholding pattern and group structure
  • Charges with holder and property details
  • Litigation, compliance and MCA filings
  • PDF report delivered after checkout
₹799 ₹999 20% off
Secure checkout · GST invoice included

Unlock the full Suven Life Sciences Limited report

Financials, compliance, directors, charges, ownership and filings for Suven Life Sciences Limited in one report.

10-year financials Directors & ownership Charges & compliance

Name History of Suven Life Sciences Limited

Suven Life Sciences Limited has undergone 2 name changes throughout its history. The company was previously known as Suven Synthesis Ltd, and Suven Pharmaceuticals Pvt Ltd. The current legal name is Suven Life Sciences Limited, reflecting the company's evolution and rebranding over time.

Company Name Status
Suven Life Sciences Limited Current
Suven Synthesis Ltd Previous
Suven Pharmaceuticals Pvt Ltd Previous

CIN History of Suven Life Sciences Limited

Suven Life Sciences Limited has one previous CIN (Corporate Identification Number): L24110AP1989PLC009713. The current CIN is L24110TG1989PLC009713, which is the unique identifier assigned by the Registrar of Companies.

CIN Status
L24110TG1989PLC009713 Current
L24110AP1989PLC009713 Previous

Associated Brands with Suven Life Sciences Limited

Suven Life Sciences Limited operates multiple associated brands including Suven Nishtaa, Suven Life Sciences, and Suven Pharma. These brands represent Suven Life Sciences Limited's diversified market presence and brand portfolio.

Brand Description Website
Suven Nishtaa
Online drug store suvennishtaa.com
Suven Life Sciences
CDMO services and CNS drug discovery pipeline are offered. suven.com
Suven Pharma
Contract manufacturing and development of APIs and formulations are provided. suvenpharm.com

Competitors & Alternatives of Suven Life Sciences Limited

Brands and companies operating in the same space as Suven Life Sciences Limited include Concord Biotech, BDR Pharmaceuticals Internationals, Almac Group and 7 more.

Competitor Description Location Founded
Concord Biotech Concord Biotech APIs and enzymes are manufactured through fermentation by the CDMO. Ahmedabad, India, India 2000
BDR Pharmaceuticals Internationals BDR Pharmaceuticals Internationals APIs and finished products are developed and manufactured. Mumbai, India, India 2003
Almac Group Almac Group Integrated CDMO services for biopharma R&D and manufacturing are offered. Craigavon, United Kingdom, United Kingdom 2001
Indoco Remedies Indoco Remedies APIs manufacturing and formulation services are provided in therapeutic segments. Mumbai, India, India 1947
Pharmaceutics International Pharmaceutics International Pharmaceutical dosage forms are manufactured by this CDMO. Hunt Valley, United States, United States 1994
Aurobindo Pharma Aurobindo Pharma Generic biocatalytic solutions are provided for pharmaceutical applications. Hyderabad, India, India 1986
Seqens Seqens Contract manufacturing services for small molecules and peptides are provided. Ecully, France, France 2003
Asymchem Asymchem APIs and peptides are developed and manufactured by Asymchem. Morrisville, United States, United States 1995
Aptuit Aptuit Contract research and development services for small molecules are offered. Greenwich, United States, United States 2004
Continuus Pharma Continuus Pharma MIT-Novartis spinoff offering continuous manufacturing solutions to remove the proverbial wall between API and FDF manufacturing in small molecule development Woburn, United States, United States 2012

Business Activity of Suven Life Sciences Limited

Suven Life Sciences Limited is engaged in the principal business activity of professional, scientific and technical, with detailed activities including scientific research and development.

Main Activity Group Code Description of Main Activity Business Activity Code Description of Business Activity Turnover Percentage
M Professional, Scientific and Technical M5 Scientific research and development Locked
Premium access

Business activity turnover details for Suven Life Sciences Limited

Turnover contribution percentages and historical activity changes require an active report plan.

  • Turnover contribution
  • Historical classifications
  • Filing-level activity changes

Verified entity values are shown only after access is granted.

Auditor Details of Suven Life Sciences Limited

Suven Life Sciences Limited is audited by KARVY & Co. (ICAI peer reviewed, certificate valid till 2024-10-31) for the financial year 2025, as reported in its NSE exchange filings. The statutory auditor is responsible for expressing an independent opinion on whether the financial statements present a true and fair view in accordance with applicable accounting standards.

Name Financial year Audit opinion
KARVY & Co. (ICAI peer reviewed, certificate valid till 2024-10-31) FY 2025 Declaration of unmodified opinion

Board of Directors of Suven Life Sciences Limited

Suven Life Sciences Limited is currently managed by 6 directors, with 18 former directors having served the organization. The current Directors play a crucial role in shaping the company's strategic direction and governance.

Current Directors
Name Designation Appointment Date Tenure Status
Santanu Mukherjee
Also directs: Suven Life Sciences Limited, Aurobindo Pharma Ltd, Sumedha Fiscal Services Ltd and 5 more
Director 15 May 2018 8 Years 3 Months Current
Sudharani Jasti
Also directs: Svsmks Property Llp, Svsmk Property Llp, Mkssjas Property Llp and 3 more
Whole-Time Director 04 Jan 2013 13 Years 7 Months Current
Venkateswarlu Jasti
Also directs: Svsmk Property Llp, Suven Life Sciences Limited, Jasti Property And Equity Holdings Private Limited and 5 more
Managing Director 04 Jan 2010 16 Years 7 Months Current
Vajja Sambasiva Rao
Also directs: Suven Life Sciences Limited
Director 30 Jan 2024 2 Years 6 Months Current
Seyed Ehtesham Hasnain
Also directs: Suven Life Sciences Limited, Aditum Life Sciences Private Limited, Dr.Reddy's Institute Of Life Sciences and 2 more
Director 30 Apr 2010 16 Years 3 Months Current
Ananthasai Padmaja Jasthi
Also directs: Suven Life Sciences Limited
Director 14 Nov 2018 7 Years 9 Months Current
View all directors

Financials of Suven Life Sciences Limited FY 2026 filings available

Suven Life Sciences Limited reported revenue of ₹7.11 Cr (up 6.89% YoY) for FY 2026.

Revenue · FY 2026
₹7.11 Cr ▲ 6.89%
Profit · FY 2026
-₹276.34 Cr ▼ 71.91%
Computed EBITDA · FY 2026
-₹270.57 Cr ▼ 74.7%
Revenue₹ Cr · Consolidated051015FY 2020: ₹14 Cr14.4FY 2020FY 2021: ₹13 Cr · -6.5% YoY13.5-6.5%FY 2021FY 2022: ₹12 Cr · -12.1% YoY11.8-12.1%FY 2022FY 2023: ₹14 Cr · +14.3% YoY13.5+14.3%FY 2023FY 2024: ₹12 Cr · -13.6% YoY11.7-13.6%FY 2024FY 2025: ₹7 Cr · -43.1% YoY6.7-43.1%FY 2025FY 2026: ₹7 Cr · +6.9% YoY7.1+6.9%FY 2026
Net Profit₹ Cr · Consolidated-300-200-1000100FY 2020: ₹94 Cr (loss)-94.2FY 2020FY 2021: ₹72 Cr (loss) · +23.4% YoY-72.2FY 2021FY 2022: ₹122 Cr (loss) · -69.1% YoY-122FY 2022FY 2023: ₹118 Cr (loss) · +3.1% YoY-118FY 2023FY 2024: ₹105 Cr (loss) · +11.2% YoY-105FY 2024FY 2025: ₹161 Cr (loss) · -53% YoY-161FY 2025FY 2026: ₹276 Cr (loss) · -71.9% YoY-276FY 2026
Quarterly Revenue₹ Cr · vs same quarter last year0123Q1'25: ₹1 Cr · -73.5% YoY1-73.5%Q1'25Q2'25: ₹3 Cr · -15.9% YoY2.6-15.9%Q2'25Q3'25: ₹2 Cr · -34.3% YoY1.6-34.3%Q3'25Q4'25: ₹1 Cr · -38.5% YoY1.5-38.5%Q4'25Q1'26: ₹2 Cr · +85.6% YoY1.9+85.6%Q1'26Q2'26: ₹1 Cr · -64.3% YoY0.9-64.3%Q2'26Q3'26: ₹3 Cr · +74.5% YoY2.8+74.5%Q3'26Q4'26: ₹2 Cr · +3.6% YoY1.5+3.6%Q4'26
Metrics FY 2026 FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
Revenue from Operations ₹7.11 Cr ₹6.66 Cr ₹11.69 Cr ₹13.54 Cr ₹11.84 Cr ₹13.48 Cr ₹14.41 Cr
Other Income ₹13.93 Cr ₹10.9 Cr ₹21.13 Cr ₹8.45 Cr ₹5.32 Cr ₹7.75 Cr ₹14.04 Cr
Total Income ₹21.04 Cr ₹17.55 Cr ₹32.82 Cr ₹21.99 Cr ₹17.16 Cr ₹21.23 Cr ₹28.45 Cr
Cost of Materials Consumed ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0
Purchases of Stock-in-Trade ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0
Changes in Inventories ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0
Employee Benefit Expense ₹24.15 Cr ₹20.82 Cr ₹18.99 Cr ₹18.62 Cr ₹21.02 Cr ₹18.53 Cr ₹17.41 Cr
Finance Costs ₹15.78 Lakh ₹4.66 Lakh ₹15.84 Lakh ₹28.91 Lakh ₹53.01 Lakh ₹81.54 Lakh ₹55.14 Lakh
Depreciation & Amortisation ₹5.61 Cr ₹5.82 Cr ₹6.5 Cr ₹6.54 Cr ₹4.39 Cr ₹4.35 Cr ₹4.17 Cr
Other Expenses ₹267.47 Cr ₹151.6 Cr ₹120.71 Cr ₹120.8 Cr ₹113.21 Cr ₹75.02 Cr ₹112.72 Cr
Total Expenses ₹297.39 Cr ₹178.3 Cr ₹146.36 Cr ₹146.26 Cr ₹139.16 Cr ₹98.71 Cr ₹134.85 Cr
Profit Before Exceptional Items & Tax -₹276.34 Cr -₹160.75 Cr -₹113.54 Cr -₹124.27 Cr -₹122 Cr -₹77.47 Cr -₹106.4 Cr
Exceptional Items ₹0 ₹0 ₹7.46 Cr ₹6 Cr ₹0 ₹0 ₹0
Profit Before Tax -₹276.34 Cr -₹160.75 Cr -₹106.08 Cr -₹118.27 Cr -₹122 Cr -₹77.47 Cr -₹106.4 Cr
Total Tax Expense ₹0 ₹0 -₹1 Cr ₹0 ₹0 -₹5.32 Cr -₹12.18 Cr
Net Profit -₹276.34 Cr -₹160.75 Cr -₹105.08 Cr -₹118.27 Cr -₹122 Cr -₹72.15 Cr -₹94.22 Cr
  attributable to Owners - - - ₹0 ₹0 ₹0 -
  attributable to NCI - - - ₹0 ₹0 ₹0 -
Other Comprehensive Income -₹1.18 Cr -₹58.33 Lakh -₹6 Lakh ₹18.99 Lakh -₹15.05 Lakh -₹30.67 Lakh -₹29.54 Lakh
Total Comprehensive Income -₹277.53 Cr -₹161.33 Cr -₹105.14 Cr -₹118.08 Cr -₹122.15 Cr -₹72.46 Cr -₹94.51 Cr
EBITDA (computed) -₹270.57 Cr -₹154.88 Cr -₹106.87 Cr -₹117.44 Cr -₹117.07 Cr -₹72.31 Cr -₹101.68 Cr
Basic EPS ₹-12.13 ₹-7.37 ₹-4.82 ₹-6.63 ₹-9.57 ₹-5.67 ₹-2.01
Diluted EPS ₹-12.13 ₹-7.37 ₹-4.82 ₹-6.63 ₹-9.57 ₹-5.67 ₹-7.40
Metrics FY 2026 FY 2025 FY 2024 FY 2023
Total Assets ₹624.21 Cr ₹135.18 Cr ₹284.9 Cr ₹388.91 Cr
Non-current Assets ₹77.51 Cr ₹59.71 Cr ₹28.23 Cr ₹137.32 Cr
Current Assets ₹546.71 Cr ₹75.47 Cr ₹256.67 Cr ₹251.59 Cr
Property, Plant & Equipment ₹55.7 Cr ₹59.47 Cr ₹27.5 Cr ₹35.73 Cr
Inventories ₹10.2 Lakh ₹23.75 Lakh ₹70.85 Lakh ₹0
Trade Receivables ₹1.51 Cr ₹1.34 Cr ₹1.29 Cr ₹80.74 Lakh
Cash & Equivalents ₹8.28 Cr ₹15.03 Cr ₹14.93 Cr ₹37.02 Cr
Equity (Net Worth) ₹591.4 Cr ₹109.99 Cr ₹270.04 Cr ₹375.32 Cr
Equity Share Capital ₹26.37 Cr ₹21.81 Cr ₹21.81 Cr ₹21.81 Cr
Borrowings (Non-current) ₹0 ₹0 ₹0 ₹0
Borrowings (Current) ₹0 ₹0 ₹0 ₹0
Total Debt (computed) ₹0 ₹0 ₹0 ₹0
Current Liabilities ₹30.9 Cr ₹23.49 Cr ₹13.52 Cr ₹11.13 Cr
Total Liabilities ₹32.81 Cr ₹25.2 Cr ₹14.86 Cr ₹13.59 Cr
The balance sheet became part of the exchange results-filing format in FY2023 - earlier years were not filed and are hidden.
Metrics FY 2026 FY 2025 FY 2024 FY 2023 FY 2022
Operating Cash Flow -₹301.79 Cr -₹154.1 Cr -₹82.62 Cr -₹207.93 Cr -₹127.54 Cr
Investing Cash Flow -₹462.11 Cr ₹154.95 Cr ₹61.59 Cr -₹155.71 Cr -₹22.23 Cr
Financing Cash Flow ₹757.15 Cr -₹75.63 Lakh -₹1.05 Cr ₹395.54 Cr ₹145.69 Cr
Capital Expenditure ₹5.08 Cr ₹37.28 Cr -₹2.42 Cr ₹2.89 Cr ₹19.77 Cr
Free Cash Flow (computed) -₹306.87 Cr -₹191.38 Cr -₹85.04 Cr -₹210.82 Cr -₹147.31 Cr
Dividends Paid ₹0 ₹0 ₹0 ₹0 ₹0
Net Change in Cash -₹6.75 Cr ₹9.31 Lakh -₹22.09 Cr ₹31.75 Cr -₹4.07 Cr
The cash-flow statement became part of the exchange results-filing format in FY2022 - earlier years were not filed and are hidden.
Metrics Q4 FY26 Q3 FY26 Q2 FY26 Q1 FY26 Q4 FY25 Q3 FY25 Q2 FY25 Q1 FY25 Q4 FY24 Q3 FY24 Q2 FY24 Q1 FY24
Revenue from Operations ₹1.52 Cr ₹2.81 Cr ₹91.92 Lakh ₹1.87 Cr ₹1.47 Cr ₹1.61 Cr ₹2.57 Cr ₹1.01 Cr ₹2.39 Cr ₹2.45 Cr ₹3.06 Cr ₹3.8 Cr
Other Income ₹6.78 Cr ₹2.77 Cr ₹3.78 Cr ₹59.98 Lakh ₹1.22 Cr ₹1.63 Cr ₹4.04 Cr ₹4.01 Cr ₹4.28 Cr ₹6.07 Cr ₹5.14 Cr ₹5.64 Cr
Total Income ₹8.3 Cr ₹5.58 Cr ₹4.7 Cr ₹2.47 Cr ₹2.69 Cr ₹3.24 Cr ₹6.61 Cr ₹5.01 Cr ₹6.67 Cr ₹8.52 Cr ₹8.2 Cr ₹9.44 Cr
Cost of Materials Consumed ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0
Purchases of Stock-in-Trade ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0
Changes in Inventories ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0
Employee Benefit Expense ₹5.83 Cr ₹6.27 Cr ₹6.08 Cr ₹5.98 Cr ₹6.07 Cr ₹4.87 Cr ₹5.2 Cr ₹4.69 Cr ₹3.46 Cr ₹5.79 Cr ₹4.45 Cr ₹5.28 Cr
Finance Costs ₹15.78 Lakh ₹0 ₹0 ₹0 ₹0 ₹79,000 ₹1.56 Lakh ₹2.31 Lakh ₹2.99 Lakh ₹3.54 Lakh ₹4.19 Lakh ₹5.12 Lakh
Depreciation & Amortisation ₹1.58 Cr ₹1.35 Cr ₹1.32 Cr ₹1.37 Cr ₹1.35 Cr ₹1.53 Cr ₹1.46 Cr ₹1.49 Cr ₹1.51 Cr ₹1.6 Cr ₹1.73 Cr ₹1.66 Cr
Other Expenses ₹46.32 Cr ₹99.89 Cr ₹74.61 Cr ₹46.64 Cr ₹39.22 Cr ₹35.95 Cr ₹49.58 Cr ₹26.85 Cr ₹29.21 Cr ₹42.85 Cr ₹22.12 Cr ₹26.53 Cr
Total Expenses ₹53.89 Cr ₹107.51 Cr ₹82.01 Cr ₹53.98 Cr ₹46.63 Cr ₹42.36 Cr ₹56.25 Cr ₹33.05 Cr ₹34.21 Cr ₹50.28 Cr ₹28.34 Cr ₹33.53 Cr
Profit Before Exceptional Items & Tax -₹45.6 Cr -₹101.92 Cr -₹77.31 Cr -₹51.52 Cr -₹43.94 Cr -₹39.12 Cr -₹49.64 Cr -₹28.04 Cr -₹27.54 Cr -₹41.76 Cr -₹20.14 Cr -₹24.09 Cr
Exceptional Items ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹7.46 Cr ₹0
Profit Before Tax -₹45.6 Cr -₹101.92 Cr -₹77.31 Cr -₹51.52 Cr -₹43.94 Cr -₹39.12 Cr -₹49.64 Cr -₹28.04 Cr -₹27.54 Cr -₹41.76 Cr -₹12.68 Cr -₹24.09 Cr
Total Tax Expense ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 -₹1 Cr ₹0 ₹0 ₹0
Net Profit -₹45.6 Cr -₹101.92 Cr -₹77.31 Cr -₹51.52 Cr -₹43.94 Cr -₹39.12 Cr -₹49.64 Cr -₹28.04 Cr -₹26.54 Cr -₹41.76 Cr -₹12.68 Cr -₹24.09 Cr
  attributable to Owners - - ₹0 ₹0 - ₹0 ₹0 ₹0 - ₹0 ₹0 ₹0
  attributable to NCI - - ₹0 ₹0 - ₹0 ₹0 ₹0 - ₹0 ₹0 ₹0
Other Comprehensive Income -₹46.66 Lakh -₹75.13 Lakh ₹8.52 Lakh -₹5.12 Lakh -₹56.98 Lakh -₹45,000 -₹45,000 -₹45,000 -₹20.24 Lakh ₹4.75 Lakh ₹4.75 Lakh ₹4.75 Lakh
Total Comprehensive Income -₹46.06 Cr -₹102.67 Cr -₹77.22 Cr -₹51.57 Cr -₹44.51 Cr -₹39.12 Cr -₹49.65 Cr -₹28.04 Cr -₹26.74 Cr -₹41.72 Cr -₹12.63 Cr -₹24.04 Cr
EBITDA (computed) -₹43.86 Cr -₹100.58 Cr -₹75.99 Cr -₹50.15 Cr -₹42.6 Cr -₹37.58 Cr -₹48.17 Cr -₹26.53 Cr -₹26 Cr -₹40.13 Cr -₹18.37 Cr -₹22.37 Cr
Basic EPS ₹-2.02 ₹-4.55 ₹-3.48 ₹-2.36 ₹-2.02 ₹-1.79 ₹-2.27 ₹-1.29 ₹-1.22 ₹-1.92 ₹-0.58 ₹-1.10
Diluted EPS ₹-2.02 ₹-4.55 ₹-3.48 ₹-2.36 ₹-2.02 ₹-1.79 ₹-2.27 ₹-1.29 ₹-1.22 ₹-1.92 ₹-0.58 ₹-1.10
Latest 12 quarters shown of 25 on record.
Metrics FY 2026 FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
Revenue from Operations ₹7.11 Cr ₹6.66 Cr ₹11.69 Cr ₹13.54 Cr ₹11.84 Cr ₹13.48 Cr ₹14.41 Cr
Other Income ₹13.91 Cr ₹10.73 Cr ₹21.13 Cr ₹8.45 Cr ₹5.32 Cr ₹7.75 Cr ₹14.04 Cr
Total Income ₹21.03 Cr ₹17.38 Cr ₹32.82 Cr ₹21.99 Cr ₹17.16 Cr ₹21.23 Cr ₹28.45 Cr
Cost of Materials Consumed ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0
Purchases of Stock-in-Trade ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0
Changes in Inventories ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0
Employee Benefit Expense ₹24.15 Cr ₹20.82 Cr ₹16.53 Cr ₹15.77 Cr ₹17.46 Cr ₹15.29 Cr ₹14.6 Cr
Finance Costs ₹15.78 Lakh ₹4.66 Lakh ₹15.84 Lakh ₹28.91 Lakh ₹53.01 Lakh ₹81.54 Lakh ₹54.03 Lakh
Depreciation & Amortisation ₹5.61 Cr ₹5.82 Cr ₹6.5 Cr ₹6.54 Cr ₹4.39 Cr ₹4.35 Cr ₹4.17 Cr
Other Expenses ₹45.97 Cr ₹37.77 Cr ₹26.1 Cr ₹25.51 Cr ₹31.02 Cr ₹28.74 Cr ₹35.08 Cr
Total Expenses ₹75.89 Cr ₹64.46 Cr ₹49.29 Cr ₹48.12 Cr ₹53.41 Cr ₹49.19 Cr ₹54.39 Cr
Profit Before Exceptional Items & Tax -₹54.86 Cr -₹47.08 Cr -₹16.47 Cr -₹26.13 Cr -₹36.25 Cr -₹27.95 Cr -₹25.94 Cr
Exceptional Items ₹0 ₹0 ₹7.46 Cr ₹6 Cr ₹0 ₹0 ₹0
Profit Before Tax -₹54.86 Cr -₹47.08 Cr -₹9.01 Cr -₹20.13 Cr -₹36.25 Cr -₹27.95 Cr -₹25.94 Cr
Total Tax Expense ₹0 ₹0 -₹1 Cr ₹0 ₹0 -₹5.32 Cr -₹12.18 Cr
Net Profit -₹54.86 Cr -₹47.08 Cr -₹8.01 Cr -₹20.13 Cr -₹36.25 Cr -₹22.63 Cr -₹13.75 Cr
Other Comprehensive Income -₹22.19 Lakh -₹5.69 Lakh -₹6 Lakh ₹18.99 Lakh -₹15.05 Lakh -₹30.67 Lakh -₹29.54 Lakh
Total Comprehensive Income -₹55.08 Cr -₹47.14 Cr -₹8.07 Cr -₹19.94 Cr -₹36.4 Cr -₹22.94 Cr -₹14.05 Cr
EBITDA (computed) -₹49.09 Cr -₹41.21 Cr -₹9.81 Cr -₹19.29 Cr -₹31.33 Cr -₹22.79 Cr -₹21.23 Cr
Basic EPS ₹-2.41 ₹-2.16 ₹-0.37 ₹-1.13 ₹-2.84 ₹-1.78 ₹-1.08
Diluted EPS ₹-2.41 ₹-2.16 ₹-0.37 ₹-1.13 ₹-2.84 ₹-1.78 ₹-1.08
Metrics FY 2026 FY 2025 FY 2024 FY 2023
Total Assets ₹1,531.06 Cr ₹808.89 Cr ₹851.48 Cr ₹860.44 Cr
Non-current Assets ₹990.35 Cr ₹751.18 Cr ₹605.34 Cr ₹619.18 Cr
Current Assets ₹540.71 Cr ₹57.71 Cr ₹246.14 Cr ₹241.26 Cr
Property, Plant & Equipment ₹55.7 Cr ₹59.47 Cr ₹27.5 Cr ₹35.73 Cr
Inventories ₹10.2 Lakh ₹23.75 Lakh ₹70.85 Lakh ₹0
Trade Receivables ₹1.51 Cr ₹1.34 Cr ₹1.29 Cr ₹80.74 Lakh
Cash & Equivalents ₹2.28 Cr ₹46.35 Lakh ₹4.4 Cr ₹26.7 Cr
Equity (Net Worth) ₹1,503.37 Cr ₹799.51 Cr ₹845.38 Cr ₹853.44 Cr
Equity Share Capital ₹26.37 Cr ₹21.81 Cr ₹21.81 Cr ₹21.81 Cr
Borrowings (Non-current) ₹0 ₹0 ₹0 ₹0
Borrowings (Current) ₹0 ₹0 ₹0 ₹0
Total Debt (computed) ₹0 ₹0 ₹0 ₹0
Current Liabilities ₹3.75 Cr ₹7.67 Cr ₹4.76 Cr ₹4.54 Cr
Total Liabilities ₹27.7 Cr ₹9.38 Cr ₹6.11 Cr ₹7 Cr
The balance sheet became part of the exchange results-filing format in FY2023 - earlier years were not filed and are hidden.
Metrics FY 2026 FY 2025 FY 2024 FY 2023 FY 2022
Operating Cash Flow -₹69.6 Cr -₹47.39 Cr ₹12.29 Cr -₹114.87 Cr -₹36.62 Cr
Investing Cash Flow -₹685.74 Cr ₹44.21 Cr -₹33.53 Cr -₹256.88 Cr -₹107.46 Cr
Financing Cash Flow ₹757.15 Cr -₹75.63 Lakh -₹1.05 Cr ₹395.54 Cr ₹145.69 Cr
Capital Expenditure ₹5.08 Cr ₹37.28 Cr -₹2.42 Cr ₹2.89 Cr ₹19.77 Cr
Free Cash Flow (computed) -₹74.68 Cr -₹84.67 Cr ₹9.87 Cr -₹117.76 Cr -₹56.39 Cr
Dividends Paid ₹0 ₹0 ₹0 ₹0 ₹0
Net Change in Cash ₹1.82 Cr -₹3.94 Cr -₹22.3 Cr ₹23.79 Cr ₹1.61 Cr
The cash-flow statement became part of the exchange results-filing format in FY2022 - earlier years were not filed and are hidden.
Metrics Q4 FY26 Q3 FY26 Q2 FY26 Q1 FY26 Q4 FY25 Q3 FY25 Q2 FY25 Q1 FY25 Q4 FY24 Q3 FY24 Q2 FY24 Q1 FY24
Revenue from Operations ₹1.52 Cr ₹2.81 Cr ₹91.92 Lakh ₹1.87 Cr ₹1.47 Cr ₹1.61 Cr ₹2.57 Cr ₹1.01 Cr ₹2.39 Cr ₹2.45 Cr ₹3.06 Cr ₹3.8 Cr
Other Income ₹6.78 Cr ₹2.77 Cr ₹3.78 Cr ₹58.9 Lakh ₹1.19 Cr ₹1.57 Cr ₹4.03 Cr ₹3.93 Cr ₹4.28 Cr ₹6.07 Cr ₹5.14 Cr ₹5.64 Cr
Total Income ₹8.3 Cr ₹5.57 Cr ₹4.7 Cr ₹2.46 Cr ₹2.66 Cr ₹3.18 Cr ₹6.61 Cr ₹4.94 Cr ₹6.67 Cr ₹8.52 Cr ₹8.2 Cr ₹9.44 Cr
Cost of Materials Consumed ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0
Purchases of Stock-in-Trade ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0
Changes in Inventories ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0
Employee Benefit Expense ₹5.83 Cr ₹6.27 Cr ₹6.08 Cr ₹5.98 Cr ₹6.07 Cr ₹4.87 Cr ₹5.2 Cr ₹4.69 Cr ₹3.46 Cr ₹4.32 Cr ₹4.21 Cr ₹4.54 Cr
Finance Costs ₹15.78 Lakh ₹0 ₹0 ₹0 ₹0 ₹79,000 ₹1.56 Lakh ₹2.31 Lakh ₹2.99 Lakh ₹3.54 Lakh ₹4.19 Lakh ₹5.12 Lakh
Depreciation & Amortisation ₹1.58 Cr ₹1.35 Cr ₹1.32 Cr ₹1.37 Cr ₹1.35 Cr ₹1.53 Cr ₹1.46 Cr ₹1.49 Cr ₹1.51 Cr ₹1.6 Cr ₹1.73 Cr ₹1.66 Cr
Other Expenses ₹11.9 Cr ₹11.43 Cr ₹12.75 Cr ₹9.89 Cr ₹10.32 Cr ₹10.04 Cr ₹11.01 Cr ₹6.4 Cr ₹5.79 Cr ₹7.33 Cr ₹6.92 Cr ₹6.05 Cr
Total Expenses ₹19.47 Cr ₹19.05 Cr ₹20.14 Cr ₹17.23 Cr ₹17.73 Cr ₹16.45 Cr ₹17.68 Cr ₹12.6 Cr ₹10.79 Cr ₹13.29 Cr ₹12.9 Cr ₹12.31 Cr
Profit Before Exceptional Items & Tax -₹11.17 Cr -₹13.47 Cr -₹15.45 Cr -₹14.78 Cr -₹15.07 Cr -₹13.27 Cr -₹11.07 Cr -₹7.67 Cr -₹4.13 Cr -₹4.77 Cr -₹4.7 Cr -₹2.87 Cr
Exceptional Items ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹7.46 Cr ₹0
Profit Before Tax -₹11.17 Cr -₹13.47 Cr -₹15.45 Cr -₹14.78 Cr -₹15.07 Cr -₹13.27 Cr -₹11.07 Cr -₹7.67 Cr -₹4.13 Cr -₹4.77 Cr ₹2.76 Cr -₹2.87 Cr
Total Tax Expense ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 -₹1 Cr ₹0 ₹0 ₹0
Net Profit -₹11.17 Cr -₹13.47 Cr -₹15.45 Cr -₹14.78 Cr -₹15.07 Cr -₹13.27 Cr -₹11.07 Cr -₹7.67 Cr -₹3.12 Cr -₹4.77 Cr ₹2.76 Cr -₹2.87 Cr
Other Comprehensive Income -₹22.45 Lakh ₹3.26 Lakh -₹1.5 Lakh -₹1.5 Lakh -₹4.64 Lakh -₹45,000 -₹45,000 -₹45,000 -₹20.24 Lakh ₹4.75 Lakh ₹4.74 Lakh ₹4.75 Lakh
Total Comprehensive Income -₹11.39 Cr -₹13.44 Cr -₹15.46 Cr -₹14.79 Cr -₹15.12 Cr -₹13.28 Cr -₹11.08 Cr -₹7.67 Cr -₹3.33 Cr -₹4.72 Cr ₹2.8 Cr -₹2.82 Cr
EBITDA (computed) -₹9.43 Cr -₹12.13 Cr -₹14.13 Cr -₹13.41 Cr -₹13.72 Cr -₹11.73 Cr -₹9.6 Cr -₹6.16 Cr -₹2.59 Cr -₹3.13 Cr -₹2.93 Cr -₹1.15 Cr
Basic EPS ₹-0.50 ₹-0.60 ₹-0.70 ₹-0.68 ₹-0.69 ₹-0.61 ₹-0.51 ₹-0.35 ₹-0.14 ₹-0.22 ₹0.13 ₹-0.13
Diluted EPS ₹-0.50 ₹-0.60 ₹-0.70 ₹-0.68 ₹-0.69 ₹-0.61 ₹-0.51 ₹-0.35 ₹-0.14 ₹-0.22 ₹0.13 ₹-0.13
Latest 12 quarters shown of 25 on record.
Want more history and ratios?
You're viewing the latest exchange-filed financials for Suven Life Sciences Limited. The full report adds 10+ years of line-item history, 20+ ratios, peer benchmarks and a downloadable PDF.
10+ years of history 20+ ratios & benchmarks Downloadable PDF

Shareholding Pattern of Suven Life Sciences Limited

As per the shareholding pattern filed with NSE for the quarter ended Mar 2026, promoters hold 70.15%, foreign institutional investors hold 0.91%, domestic institutional investors hold 4.62%, retail and other public shareholders hold 24.32% of Suven Life Sciences Limited. The company had 63,915 shareholders on record.

Promoters: 70.15%DII (Domestic Institutional): 4.62%FII (Foreign Institutional): 0.91%Retail & Others: 24.32%
Mar 2026
QUARTER
70.15% Promoters
4.62% DII (Domestic Institutional)
0.91% FII (Foreign Institutional)
24.32% Retail & Others
Promoter holding - history
Now 70.15% · Mar 2026High 70.27% · Jun 2024Low 59.57% · Dec 2015
58%61.5%65%68.5%72%Dec 2015Jun 2018Dec 2020Mar 2023Jul 2025Dec 2015: 59.57%Mar 2016: 60.00%Jun 2016: 60.00%Sep 2016: 60.00%Dec 2016: 60.00%Mar 2017: 60.00%Jun 2017: 60.00%Sep 2017: 60.00%Dec 2017: 60.00%Mar 2018: 60.00%Jun 2018: 60.00%Sep 2018: 60.00%Dec 2018: 60.00%Mar 2019: 60.00%Jun 2019: 60.00%Sep 2019: 60.00%Dec 2019: 60.00%Mar 2020: 60.00%Jun 2020: 60.00%Sep 2020: 60.00%Dec 2020: 60.00%Mar 2021: 60.00%Jun 2021: 60.00%Sep 2021: 60.00%Dec 2021: 60.00%Mar 2022: 64.98%Jun 2022: 64.98%Sep 2022: 64.98%Nov 2022: 64.98%Dec 2022: 69.57%Mar 2023: 69.57%Jun 2023: 69.57%Sep 2023: 69.57%Dec 2023: 69.57%Mar 2024: 69.57%Jun 2024: 70.27%Sep 2024: 70.27%Dec 2024: 70.27%Mar 2025: 70.27%Jun 2025: 70.27%Jul 2025: 67.43%Sep 2025: 67.36%Dec 2025: 67.36%Mar 2026: 70.15%70.27%59.57%70.15%
Shareholding trend - last 6 quarters
Mar 2026Dec 2025Sep 2025Jul 2025Jun 2025Mar 2025
Promoters70.15%67.36%67.36%67.43%70.27%70.27%
Public29.85%32.64%32.64%32.57%29.73%29.73%
Shareholding history - year on year (as at 31 March)
Mar 2026Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020Mar 2019Mar 2018Mar 2017Mar 2016
Promoters70.15%70.27%69.57%69.57%64.98%60.00%60.00%60.00%60.00%60.00%60.00%
Public29.85%29.73%30.43%30.43%35.02%40.00%40.00%40.00%40.00%40.00%40.00%
Promoter change (YoY, %pts)-0.12+0.70+0.00+4.59+4.98+0.00+0.00+0.00+0.00+0.00-

Board & Governance of Suven Life Sciences Limited

As per the corporate governance filing with NSE for the quarter ended 31-MAR-2026, the board of Suven Life Sciences Limited has 6 directors - 3 independent and 2 executive. The board is chaired by VENKATESWARLU JASTI.

DirectorPositionOn board sinceListed boards
VENKATESWARLU JASTI Executive Director · MD · Chairperson 1989-03-09 2
SUDHARANI JASTI Executive Director 1989-03-09 1
SEYED EHTESHAM HASNAIN Non-Executive - Non Independent Director 2010-04-30 1
SANTANU MUKHERJEE Non-Executive - Independent Director 2018-05-15 4
ANANTHASAI PADMAJA JASTHI Non-Executive - Independent Director 2018-11-14 1
VAJJA SAMBASIVA RAO Non-Executive - Independent Director 2024-01-30 1
Board Committees
CommitteeMembers
Audit Committee SANTANU MUKHERJEE (Chairperson), ANANTHASAI PADMAJA JASTHI, VAJJA SAMBASIVA RAO
Nomination and remuneration committee SANTANU MUKHERJEE (Chairperson), SEYED EHTESHAM HASNAIN, ANANTHASAI PADMAJA JASTHI, VAJJA SAMBASIVA RAO
Stakeholders Relationship Committee VAJJA SAMBASIVA RAO (Chairperson), ANANTHASAI PADMAJA JASTHI, VENKATESWARLU JASTI
Risk Management Committee VENKATESWARLU JASTI (Chairperson), SANTANU MUKHERJEE, VAJJA SAMBASIVA RAO, MOHANKUMAR MALLARAPU
Corporate Social Responsibility Committee VAJJA SAMBASIVA RAO (Chairperson), SEYED EHTESHAM HASNAIN, VENKATESWARLU JASTI

Charges & Borrowings of Suven Life Sciences Limited

Open charges
₹0
Satisfied charges
₹239.04 Cr
Breakdown by lending institutions
State Bank of India₹147.51 Cr
Bank of Bahrain and Kuwait Bsc₹36.00 Cr
Bank of India₹22.63 Cr
State of Bank Patiala₹20.00 Cr
Export -- Import Bank of India₹6.00 Cr
Others₹6.90 Cr
Latest charge details
DateLenderAmountStatus
06 Dec 2012 Bank of Bahrain and Kuwait Bsc ₹6 Cr Satisfied
24 Aug 2012 Bank of Bahrain and Kuwait Bsc ₹30 Cr Satisfied
17 Feb 2011 Bank of India ₹22.63 Cr Satisfied
14 Jul 2010 State of Bank Patiala ₹20 Cr Satisfied
30 Aug 2007 State Bank of India ₹25.35 Cr Satisfied

Total charge records: 14 View all charges

Employees and EPFO Compliance at Suven Life Sciences Limited

Suven Life Sciences Limited has a workforce of 137 employees as of Apr 06, 2024.

Employee count
137
Active EPFO establishments
3
Employee growth
7.03%
Premium access

Employee and EPFO history for Suven Life Sciences Limited

Monthly headcount, contribution history, establishment records, and filing compliance require an active report plan.

  • Monthly headcount
  • PF contributions
  • ECR filing status
  • Establishment history

Verified entity values are shown only after access is granted.

GST Compliance of Suven Life Sciences Limited

Premium access

GST registrations and filing compliance for Suven Life Sciences Limited

State-wise registrations, return filing status, HSN and SAC details, and jurisdiction records require an active report plan.

  • GSTIN registrations
  • State-wise filing status
  • HSN and SAC details
  • Tax jurisdiction records

Verified entity values are shown only after access is granted.

Credit Ratings, Litigation & Regulatory Alerts for Suven Life Sciences Limited

Premium access

Credit ratings, litigation, and regulatory alerts for Suven Life Sciences Limited

Agency ratings, court records, regulatory events, and entity-specific compliance alerts require an active report plan.

  • Rating history
  • Court and tribunal cases
  • Regulatory alerts
  • Director-linked violations

Verified entity values are shown only after access is granted.

MSME Payment Delays by Suven Life Sciences Limited

Premium access

MSME payment history for Suven Life Sciences Limited

Amounts outstanding to micro and small suppliers, delay reasons, and MSME-1 filing history require an active report plan.

  • Outstanding amounts
  • Delay periods and reasons
  • MSME-1 filing history
  • Vendor payment signals

Verified entity values are shown only after access is granted.

Subsidiaries & Group Companies of Suven Life Sciences Limited

Premium access

Corporate group structure for Suven Life Sciences Limited

Parent, subsidiary, associate, joint venture, and ownership records require an active report plan.

  • Parent company
  • Subsidiaries and ownership
  • Associates and joint ventures
  • Entity investments

Verified entity values are shown only after access is granted.

MCA Filings & Documents of Suven Life Sciences Limited

Premium access

MCA filings and documents for Suven Life Sciences Limited

Official forms, annual returns, financial statements, charge filings, and document dates require an active report plan.

  • Incorporation documents
  • Annual returns and statements
  • Charge filings
  • Complete filing index

Verified entity values are shown only after access is granted.

Recent Activity on Suven Life Sciences Limited

Directors
05 Feb 2026
Sangeetha Laxmi Kandari was appointed as a Company Secretary on 05 Feb 2026 & has been associated with this company since 6 months 18 days.
Activity
22 Aug 2025
Suven Life Sciences Limited last Annual general meeting of members was held on 22 Aug 2025 as per latest MCA records.
Activity
31 Mar 2025
Suven Life Sciences Limited has filed its annual Financial statements for the year ended 31 Mar 2025 with Roc Hyderabad.
Directors
30 Jan 2024
Vajja Sambasiva Rao was appointed as a Director on 30 Jan 2024 & has been associated with this company since 2 years 6 months.
Charges
07 Jan 2021
A charge registered on 06 Dec 2012 via Charge ID 10393384 with Bank Of Bahrain And Kuwait Bsc was fully satisfied on 07 Jan 2021.
Charges
03 Dec 2020
A charge registered on 26 Feb 1990 via Charge ID 90135165 with State Bank Of India was fully satisfied on 03 Dec 2020.

Recent News on Suven Life Sciences Limited

Frequently Asked Questions about Suven Life Sciences Limited

Suven Life Sciences Limited is an active public limited company in the pharma sector based in Hyderabad, Telangana, India. It was incorporated on 09 March 1989 (37+ years old) and is registered under CIN L24110TG1989PLC009713. Listed on BSE: 530239 and NSE: SUVEN. The company has 137 employees.

Suven Life Sciences Limited reported revenue of ₹7.11 Cr for FY 2026 (up 6.89% YoY) based on consolidated NSE filings.

The current directors of Suven Life Sciences Limited are:

The primary industry of Suven Life Sciences Limited is pharma. The company specifically operates in pharma contract r and d. The company is currently active in this sector.

Yes. Suven Life Sciences Limited is listed on both BSE (code: 530239) and NSE (symbol: SUVEN).

Suven Life Sciences Limited can be reached at the registered office: Door No. 8 – 2 – 334 6Th Floor Sde Serene Chambers Road No. 5 Avenue 7 Banjara Hills, Hyderabad, Telangana, India – 500034, or through the website suven.com.

7M+ Indian companies. One platform.

Financials, directors, compliance, charges and shareholding - sourced from MCA, SEBI and RBI filings.

Subscription plans available